Novo Nordisk partners with Vivtex in a $2.1 billion deal to enhance oral biologic drug delivery, targeting obesity treatment advancements.
Browsing: M&A and Licensing
News and insights on mergers, acquisitions, licensing deals, and strategic collaborations across the global pharma industry.
Lilly CSL $100M deal involves licensing a monoclonal antibody targeting IL-6, with CSL retaining rights for end-stage kidney disease.
Madrigal RNAi drug deal involves a $4.4 billion agreement with a China-based biotech for six preclinical medicines.
Lilly acquires Orna for $2.4 billion, enhancing its genetic medicine portfolio with in vivo CAR-T technology.
Lilly Innovent Biologics alliance could reach $9 billion, focusing on drug development in China.
Halozyme acquires a biotech startup for up to $400 million, enhancing its drug delivery capabilities.
China drug licensing deals for early-stage prospects are expected to rise, focusing on cell and gene therapies.
Cormorant SPAC deal secures $150M for a new biotech merger, marking its third since 2022 amid a rebound in SPAC activity.
Corxel GLP-1 Obesity Pill receives $287M funding to support its development, licensed from Vincentage in China.
Bristol Myers partners with Janux in a deal worth up to $850 million, focusing on T cell engagers for cancer treatment.